Recent Quotes
My Watchlist
Indicators
Local Stocks
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Vertex Pharmaceuticals (NQ:VRTX)

477.25 -8.14 (-1.68%)
Streaming Delayed Price Updated: 10:49 AM EDT, Jul 13, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Vertex Pharmaceuticals

< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
News headline image
3 Market-Beating Stocks Worth Investigating
Companies that consistently increase their sales, margins, or returns on capital are usually rewarded with the best returns, and those that can do all three ... 
Via StockStory
News headline image
The Best Biotech Stocks to Buy in 2026 ↗
They have at least one thing in common: An exciting pipeline. 
Via The Motley Fool
Topics ETFs
News headline image
Vertex Presents New Data on CASGEVY®, Including First European Presentation of Data in Children Ages 5–11, at the European Hematology Association Congress and Announces Additional Global Regulatory Submissions
From Vertex Pharmaceuticals Incorporated
Via Business Wire
VERTEX PHARMACEUTICALS INC (NASDAQ:VRTX): Affordable Growth with Strong Fundamentals ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX): Strong Growth Meets a Technical Setup for a Potential Breakout ↗
Via Chartmill
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) Fits the Affordable Growth Profile With Strong Earnings and Reasonable Valuation ↗
Via Chartmill
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 Estimates as New Drug Launches Drive Diversification ↗
Via Chartmill
News headline image
Kyverna Therapeutics vs. Vertex Pharmaceuticals: Which Drug Developer Stock Is a Better Buy in 2026? ↗
A clinical-stage innovator faces off against an established biotech powerhouse, each with distinct financials and risk profiles shaping their 2026 outlook. 
Via The Motley Fool
News headline image
CRISPR Therapeutics Has $2.4 Billion in Cash and an Approved Drug. Why Is Its Stock Trading Nearly 40% Below the Wall Street Consensus? ↗
The company seems to be doing everything it's supposed to be doing; the stock just isn't responding. 
Via The Motley Fool
News headline image
Vertex Presents New Data on ALYFTREK® at European Cystic Fibrosis Conference
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
The Best Stocks to Invest $500 in Right Now ↗
The market is underestimating these companies' long-term prospects. 
Via The Motley Fool
News headline image
Vertex to Participate in the Goldman Sachs 47th Annual Global Healthcare Conference on June 10
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex Announces US FDA Acceptance of Biologics License Application for Accelerated Approval of Povetacicept in IgA Nephropathy
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
2 Healthcare Stocks with Exciting Potential and 1 Facing Challenges
Personal health and wellness is one of the many secular tailwinds for healthcare companies. But financial performance has lagged recently as players offloade... 
Via StockStory
News headline image
Better Gene-Editing Stock: CRISPR Therapeutics or Beam Therapeutics? ↗
Are there significant gains ahead for one (or both) of these innovative biotechs? 
Via The Motley Fool
Which S&P500 stocks are moving on Tuesday? ↗
Via Chartmill
News headline image
1 Top Wall Street Analyst Thinks CRISPR Therapeutics Could More Than Double. Should You Buy the Stock Hand Over Fist? ↗
The biotech's innovative platform could pay off. 
Via The Motley Fool
News headline image
Vertex to Participate in Upcoming May Investor Conferences
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
5 Must-Read Analyst Questions From Vertex Pharmaceuticals’s Q1 Earnings Call
Vertex Pharmaceuticals' first quarter results reflected balanced growth across its cystic fibrosis franchise and newly launched therapies, with management hi... 
Via StockStory
Topics Earnings
News headline image
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Is This Millionaire-Maker Biotech Stock a Buy Right Now? ↗
The market wasn't impressed by its latest quarterly update. 
Via The Motley Fool
Topics Initial Public Offering
News headline image
Vertex (VRTX) Q1 2026 Earnings Call Transcript ↗
Vertex (VRTX) Q1 2026 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Pharmaceuticals Reports Mixed Q1 Results ↗
Vertex Pharmaceuticals Inc (NASDAQ:VRTX) reports financial results for the first quarter after the market close on Monday. 
Via Benzinga
News headline image
Vertex Pharmaceuticals (NASDAQ:VRTX) Beats Q1 CY2026 Sales Expectations
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) beat Wall Street’s revenue expectations in Q1 CY2026, with sales up 7.8% year on year to $2.99 billion. ... 
Via StockStory
News headline image
Vertex Reports First Quarter 2026 Financial Results
From Vertex Pharmaceuticals Incorporated
Via Business Wire
News headline image
Vertex (VRTX) Q2 2025 Earnings Call Transcript ↗
Vertex (VRTX) Q2 2025 Earnings Call Transcript 
Via The Motley Fool
Topics Earnings
News headline image
Vertex Pharmaceuticals (VRTX) Q1 Earnings: What To Expect
Biotech company Vertex Pharmaceuticals (NASDAQ:VRTX) will be reporting results this Monday after the bell. Here’s what investors should know. Vertex Pharmace... 
Via StockStory
News headline image
Got $1,000? Which of These Beaten-Down Healthcare Stocks Is Worth Buying? ↗
These longtime market beaters may not have peaked yet. 
Via The Motley Fool
Topics World Trade
News headline image
Set It and Forget It: 3 Monster Stocks Worth Holding Through Whatever Comes Next ↗
They may suffer the occasional knee-jerk setback. By and large, though, investors understand these companies are capable of standing up to almost any challenge. 
Via The Motley Fool
Topics Credit Cards Economy
News headline image
Want to Build Real Wealth in Healthcare? These Stocks Are Worth Considering ↗
These companies are leaders in their fields. 
Via The Motley Fool
< Previous 1 2 3 4 5 6 7 8 9
...
75 76 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.